In the phase 3 ASTRAEA study, abatacept demonstrated significant efficacy compared with placebo for peripheral arthritis; however, numerical improvements in dactylitis, enthesitis, and skin domains did not reach statistical significance (Table 4 ; Fig. 3 ), and nail disease was not assessed [ 59 ].
← all excerpts
A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis.
1
—
—